In 2004 the World Allergy Organization’s Specialty and Training Council conducted a survey of World Allergy Organization (WAO) member societies to obtain information about the status of the specialty of allergy worldwide. Responses were received from 33 countries, representing a population of 1.39 billion people, of whom it was estimated that 22% may suffer from some form of allergic disease. Allergy was reported by 23 respondents to be a certified or accredited specialty in their country, and the number of certified allergists per head of population ranged from 1:25 million to 1:16,000. Allergists were ranked as the fifth most likely clinicians to see cases of allergic asthma, third most likely to see allergic rhinitis, and fourth most likely to see eczema or sinusitis. Nine countries only reported that children with allergic diseases would be seen by a pediatrician with appropriate training. The survey results highlight a pressing need for the development of allergy services worldwide.

1.
Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis and atopic eczema: ISAAC. The International Study of Asthma and Allergies in Childhood (ISAAC) Steering Committee. Lancet 1998;351:1225–1232.
2.
European Community Respiratory Health Survey: Variations in the prevalence of respiratory symptoms, self reported asthma attacks and use of asthma medication in the European community respiratory health survey ECRHS. Eur Respir J 1996;9:687–695.
3.
Grundy J, Matthews S, Bateman B, et al: Rising prevalence of allergy to peanut in children: data from two sequential cohorts. J Allergy Clin Immunol 2002;110:784–789.
4.
Sheikh A, Alves B: Hospital admissions for anaphylaxis: time trend study. Br Med J 2000;320:1441.
5.
Garabrant DH, Schweitzer S: Epidemiology of latex sensitisation and allergies in health care workers. J Allergy Clin Immunol 2002;110:582–595.
6.
Demoly P, Bousquet J: Epidemiology of drug allergy. Curr Opin Allergy Clin Immunol 2001;1:305–310.
7.
Bousquet J: Allergy as a global problem: think globally act globally. Allergy 2000;57:661–662.
8.
Steinman H, Donson H, Kawalski M, Toerien A, Potter PC: Bronchial hyper-responsiveness in urban, periurban and rural South African children. Pediatr Allergy Immunol 2003;14:383–393.
9.
Maziak W, von Mutius E, Keil U, et al: Predictors of health care utilisation of children with asthma in the community. Pediatr Allergy Immunol 2004;14:166–171.
10.
Glaxo Wellcome: Asthma in America National Survey. Washington, Glaxo Wellcome, 1998.
11.
Weiss KB, Gurgen PJ, Hogson TA: An economic evaluation of asthma in the United States. N Engl J Med 1992;326:862–866.
12.
Allergy: The Unmet Need. A Blueprint for Better Patient Care. A report of the Royal College of Physicians Working Party on the Provision of Allergy Services in the UK. London, Royal College of Physicians, 2003.
13.
House of Commons Health Committee: The Provision of Allergy Services 6th Report of Session 2003/2004. House of Commons. London, The Stationery Office, HC696-1.
14.
Warner JO: The allergy paradox. Pediatr Allergy Immunol 2004;15:287–288.
15.
Grupp-Phelan J, Lozars P, Fishman P: Health care utilisation and cost in children with asthma and selected comorbidities. J Asthma 2001;38:363–373.
16.
NSF for Children, Young People and Maternity Services. London, Department of Health Publications, 2004.
17.
van den Akker-van Marle ME, Bruil J, Detmar SB: Evaluation of cost disease: assessing the burden to society of asthma in children in the European Union. Allergy 2005;60:140–149.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.